Table 1.
Characteristic of baseline demography of enrolled patients.
| Variable | Total |
|---|---|
| (n = 21) | |
| Female/Male | 18/3 (85.71/14.29%) |
| Age (year) | 51.29 ± 10.29 |
| Hypertension | 4 (19.05%) |
| Diabetes (type 2) | 5 (23.81%) |
| TNM stage | |
| I | 18 (85.71%) |
| II | 3 (14.29%) |
| Tumor size (cm) | 1.40 (0.9–1.6) |
| Tumor multifocality | 2 (9.52%) |
| Extrathyroid invasion | 6 (28.57%) |
| I-131 treatment | |
| No | 6 (28.57%) |
| 1 time | 12 (57.14%) |
| 2 times | 3 (14.29%) |
| I-131 cumulative dose (mCi) | (0–300) |
| 30 | 11 (52.38%) |
| 60 | 1 (0.47%) |
| 120 | 1 (0.47%) |
| 130 | 1 (0.47%) |
| 300 | 1 (0.47%) |
| ATA, ≥3 (IU/mL) | 10 (47.62%) |
| TPO Ab, ≥3 (IU/mL) | 6 (28.57) |
| Post-operative TSH (IU/mL) | 23.30 (1.00–82.30) |
| MACIS | 6.24 (5.64–6.85) |
| ≥7 | 5 (23.81%) |
| LNs Metastasis | 8 (38.10%) |
ATA: anti-thyroglobulin antibody; TPO Ab: thyroid peroxidase antibody; Categorical data are presented as n (%); Continuous data with unnormal distribution are presented as median (IQR; interquartile).